Видео ютуба по тегу Speaker: Martin Reck

Prof. Martin Reck on ELCC 2017 and what makes it a unique lung cancer conference
Prof. Martin Reck on ELCC 2017 and what makes it a unique lung cancer conference
Targeted therapies for advanced NSCLC
Targeted therapies for advanced NSCLC
The LUME BioNIS trial: an exploratory study into lung cancer biomarkers
The LUME BioNIS trial: an exploratory study into lung cancer biomarkers
Negative results from trial of roniciclib compared to platinum-based chemotherapy for SCLC
Negative results from trial of roniciclib compared to platinum-based chemotherapy for SCLC
Important topics at ESMO 2017
Important topics at ESMO 2017
LungART clinical trial update
LungART clinical trial update
Virtual oncology meetings
Virtual oncology meetings
The JAVELIN 100 study: a trial to improve lung cancer treatment
The JAVELIN 100 study: a trial to improve lung cancer treatment
The genetic landscape of lung cancer
The genetic landscape of lung cancer
Biomarkers are revolutionizing the treatment landscape for NSCLC
Biomarkers are revolutionizing the treatment landscape for NSCLC
The potential of targeted and immune therapies in SCLC
The potential of targeted and immune therapies in SCLC
Immunotherapy updates from WCLC 2021
Immunotherapy updates from WCLC 2021
Treatment sequecing strategies in advanced NSCLC
Treatment sequecing strategies in advanced NSCLC
IMpower150: atezolizumab, chemotherapy and bevacizumab for NSCLC
IMpower150: atezolizumab, chemotherapy and bevacizumab for NSCLC
Striking results from the PACIFIC trial
Striking results from the PACIFIC trial
Immunotherapy at the 10th European Lung Cancer Conference 2016
Immunotherapy at the 10th European Lung Cancer Conference 2016
SB8: a bevacizumab biosimilar for NSCLC
SB8: a bevacizumab biosimilar for NSCLC
Crossing the PACIFIC: will immunotherapy cure lung cancer?
Crossing the PACIFIC: will immunotherapy cure lung cancer?
How pembrolizumab will change the management of advanced lung cancer
How pembrolizumab will change the management of advanced lung cancer
IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC
KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC